Pharsight

Aaa Usa Novartis patents expiration

1. Locametz patents expiration

LOCAMETZ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11369590 AAA USA NOVARTIS PSMA binding ligand-linker conjugates and methods for using
Aug, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Mar 23, 2025

Drugs and Companies using GALLIUM GA-68 GOZETOTIDE ingredient

Market Authorisation Date: 23 March, 2022

Treatment: For use after radiolabeling with gallium-68, for positron emission tomography of prostate-specific membrane antigen (psma)-positive lesions in men with prostate cancer

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

LOCAMETZ family patents

Family Patents

2. Pluvicto patents expiration

PLUVICTO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11318121 AAA USA NOVARTIS PSMA binding ligand-linker conjugates and methods for using
Aug, 2028

(4 years from now)

US10406240 AAA USA NOVARTIS PSMA binding ligand-linker conjugates and methods for using
Aug, 2028

(4 years from now)

US10398791 AAA USA NOVARTIS Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
Oct, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 23, 2027

Drugs and Companies using LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ingredient

NCE-1 date: 2026-03-23

Market Authorisation Date: 23 March, 2022

Treatment: For treatment of adult patients with prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor (ar) pathwa...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

PLUVICTO family patents

Family Patents